Topical Postbiotics Show Promise for Acne, Eczema
-
By
-
Meg Barbor
-
March 26, 2026
-
2 min
Clinical Report: Topical Postbiotics Show Promise for Acne, Eczema
Overview
Topical postbiotics may provide a novel approach for managing acne and atopic dermatitis, showing significant improvements in inflammation and skin barrier function. A review of 16 studies indicated reductions in disease severity and lesion counts, suggesting their potential as adjunct therapies.
Background
Acne and atopic dermatitis are prevalent inflammatory skin conditions that can significantly impact quality of life. Traditional treatments often carry risks of irritation and antimicrobial resistance. Postbiotics, as nonliving microbial components, present a promising alternative that may enhance skin health without the risks associated with live microbial therapies.
Data Highlights
| Condition | Improvement | Lesion Reduction |
|---|---|---|
| Acne | Inflammatory lesions reduced | 50% to 70% |
| Eczema | Reduced disease severity and itching | Improved skin barrier function |
Key Findings
- Postbiotics may influence the skin microbiome and reduce inflammation.
- In acne, postbiotics were linked to decreased oil production and inhibition of Cutibacterium acnes.
- Patients with eczema experienced longer periods between flares and improved skin barrier function.
- Some studies reported favorable tolerability profiles for postbiotic treatments.
- Evidence for postbiotics in rosacea remains limited, highlighting a gap for future research.
Clinical Implications
Topical postbiotics may serve as a safe adjunct or alternative to traditional acne and eczema treatments, particularly for patients with concerns about irritation or antimicrobial resistance. Clinicians should consider these formulations as part of a comprehensive treatment strategy while remaining aware of the current guidelines.
Conclusion
The findings suggest that topical postbiotics could be a valuable addition to dermatologic therapies for acne and eczema, warranting further investigation to establish their role in clinical practice.
References
- Cureus, 2023 -- Topical Postbiotics Show Promise for Acne, Eczema
- American Academy of Dermatology, 2024 -- Updated Guidelines for Acne Management
- MDedge Dermatology, 2025 -- Topical Streptococcus Postbiotic Emollient Safe and Effective in Atopic Dermatitis
- the asco post — AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
- Dermatology and Therapy (Springer) — A Prebiotic and Panthenol-Containing Repair Balm Improves Tolerability of Topical 5-Fluorouracil Field Therapy for Actinic Keratoses: A Randomised Controlled Trial
- Endocrine Reviews — Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease
- Ophthalmology Management — Research Digest
- AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
- A Prebiotic and Panthenol-Containing Repair Balm Improves Tolerability of Topical 5-Fluorouracil Field Therapy
- Postbiotic Impact on Host Metabolism and Immunity Provides Therapeutic Potential in Metabolic Disease
- American Academy of Dermatology issues updated guidelines for the management of acne
- Topical Streptococcus Postbiotic Emollient Safe and Effective in Atopic Dermatitis | MDedge Dermatology
- Prebiotics, Probiotics, and Postbiotics for Acne Vulgaris: A Systematic Review - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
